Physician profile
Reginald A Ebirim
NPI 1396702957
$2,103.42
in general payments reported to CMS, 2019-2025
17 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $153 · 2021: $392 · 2022: $181 · 2023: $344 · 2024: $510 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $308.30 | 2020-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.48 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $266.29 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $232.79 | 2024-2025 | Vemlidy |
| Melinta Therapeutics, LLC | $210.14 | 2019-2023 | Orbactiv, Kimyrsa |
| Pfizer INC. | $178.72 | 2023-2025 | |
| Lilly USA, LLC | $159.05 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $102.46 | 2021-2023 | Shingrix, Trelegy Ellipta |
| Abbvie INC. | $69.43 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $69.19 | 2023 | Xarelto |
| Exact Sciences Corporation | $68.59 | 2025 | The Cologuard Plus Collection Kit |
| Genentech USA, INC. | $63.24 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $39.37 | 2023 | Farxiga |
| Phadia US INC. | $18.83 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.74 | 2024 | Strensiq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linus Health, INC. | $15.85 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reginald Ebirim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.